Navigation Links
Research defines timeframes, factors to deem early stage lung cancer cured
Date:8/2/2010

In patients with non-small cell lung cancer (NSCLC), five-year disease-free survival is currently the benchmark of cure. However, there are two issues that remain with the follow-up standards: (1) When can cure be declared with confidence and (2) for how long should follow-up examination be continued?

In order to define a strategy for long-term follow-up for early stage lung cancer patients, research published in the August edition of the Journal of Thoracic Oncology (JTO) quantified the risk of late recurrence in patients with stage IA NSCLC who remained recurrence-free for more than five years after complete tumor resection. Overall, the findings indicate that in patients with stage IA NSCLC without vascular invasion (cancer cells within blood vessels), five years may be sufficient to declare that the patients are cured. In contrast, patients with stage IA NSCLC with vascular invasion need follow-up until at least nine years after resection.

In this study, the research team identified a total of 519 patients with stage IA NSCLC who underwent complete resection between August 1992 and December 2002. Recurrence-free probability was measured from the benchmark of five years after primary tumor resection to the date of first recurrence or last follow-up. Of the 519 patients, 434 remained recurrence-free for the first five years. Among these, only 21 (4.8 percent) developed late recurrence more than five years after resection.

The researchers identified one independent significant predictor of late recurrence in stage IA five-year recurrence-free survivors: the presence of vascular invasion. The five-year recurrence-free probability from the benchmark was 84 percent for patients with vascular invasion and 95 percent for patients without vascular invasion.

Summarizing the findings, lead investigator, Ryo Maeda, MD, explains that "If they are recurrence-free, patients without vascular invasion may be declared cured at five years after resection. On the other hand, patients with stage IA NSCLC with vascular invasion, five years without recurrence is not sufficient to conclude that NSCLC is cured."


'/>"/>

Contact: Megan Richter
mrichter@spectrumscience.com
202-587-2556
International Association for the Study of Lung Cancer
Source:Eurekalert  

Related medicine news :

1. Women attracted to men in red, research shows
2. Researchers develop advanced search tool to help physicians sort and retrieve vital EMR data
3. Reality TV, cosmetic surgey linked, says Rutgers-Camden researcher
4. MSU targets womens health research with $2.5 million grant
5. Researchers identify key enzyme in DNA repair pathway
6. A breakthrough in tuberculosis research
7. Researchers study benefits of white button mushrooms
8. AWARD Fellowship highlights critical role of African women in agricultural research
9. Use of decision-aid program increases safety for women experiencing abuse, researchers find
10. Trainee publication highlights success of US-China agricultural injury research training project
11. Researchers uncover biological rationale for why intensive lupus treatment works
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Research defines timeframes, factors to deem early stage lung cancer cured
(Date:5/3/2016)... ... 2016 , ... Healing Cancer in This Century is a Summit ... recovery and is offered by creator and visionary Carlos Caridad. Healing Cancer In ... considering medical and healing modalities of the fields of Integrative, Alternative, Energetic, Holistic ...
(Date:5/3/2016)... ... ... Calvary Hospital recently hosted a reception to mark a new music program ... Mary, Manning Walsh Home (MMW) in Manhattan. , During the school year, a ... once a week. The music brings a lot of joy to the patients, family ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... a process that selects DNA or RNA from a random library of sequences ... be used as drugs or diagnostic agents. SELEX selection is commonly performed using ...
(Date:5/3/2016)... ... May 03, 2016 , ... Cosmetic surgeon Dr. Mark Youssef ... 2014, incorporating the injectable filler into his menu of services to give his patients ... than a year later, he’s still improving his approach to ensure he stays at ...
(Date:5/3/2016)... WORTH, Texas (PRWEB) , ... May 03, 2016 , ... ... of the signs of pet anxiety. "Pet owners often think anxiety only manifests ... sending stress signals in other ways, and there’s things that be done about it,” ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... Life Sciences, Product Development Capabilities in ... Customer Base . Indegene ( ... announced the acquisition of Skura Corporation,s life science ... in adaptive sales enablement technology for life science ...
(Date:4/28/2016)... 28, 2016   Click here for supplemental ... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ... agreement to acquire Valley Campus Pharmacy, Inc., doing ... leading specialty pharmacy that provides individualized patient care, ... . In 2015, TNH generated approximately $400 million ...
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
Breaking Medicine Technology: